Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down on Disappointing Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price gapped down prior to trading on Thursday following a weaker than expected earnings announcement. The stock had previously closed at $45.75, but opened at $41.75. Collegium Pharmaceutical shares last traded at $44.0720, with a volume of 80,708 shares.

The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The firm had revenue of $205.45 million during the quarter, compared to the consensus estimate of $206.36 million. During the same period last year, the business earned $1.77 earnings per share. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year.

Key Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Record full-year and solid Q4 revenue growth — Collegium reported Q4 net revenue of $205.4M (up ~13% YoY) and record FY‑2025 net revenue of $780.6M (up ~24% YoY), showing continued demand expansion. GlobeNewswire: Q4 & FY2025 Results
• Positive Sentiment: Q4 revenue essentially met expectations — coverage noted revenue was broadly in line with estimates, which tempers downside risk from the quarter. Yahoo: Q4 Revenue In Line
• Neutral Sentiment: FY‑2026 revenue guidance set to $805M–$825M, which is roughly in line with the consensus (~$806.8M); guidance keeps expectations steady but offers limited upside surprise. GlobeNewswire: Guidance
• Neutral Sentiment: Investor focus on Jornay PM and product mix — several previews and previews/analyses highlighted Jornay PM performance and pipeline/market dynamics that could influence growth cadence. Investing.com: Jornay PM in Focus
• Negative Sentiment: Q4 EPS missed estimates — COL reported $2.04 EPS vs. consensus $2.20, a shortfall that weighed on near-term earnings confidence. MarketBeat: Q4 EPS & Call
• Negative Sentiment: Management did not provide a clear EPS range in its FY‑2026 guidance (revenue range was given but EPS guidance was omitted in the update), which can create uncertainty and pressure sentiment despite revenue guidance being in line. GlobeNewswire: Full Results & Guidance

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on COLL shares. Barclays decreased their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th. Needham & Company LLC increased their price objective on Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.40.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 17,600 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president owned 103,613 shares of the company’s stock, valued at $4,991,038.21. This trade represents a 14.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction on Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the sale, the director directly owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This trade represents a 6.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.51% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors have recently modified their holdings of the stock. Illinois Municipal Retirement Fund raised its position in shares of Collegium Pharmaceutical by 1.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock valued at $605,000 after acquiring an additional 278 shares during the period. Vident Advisory LLC raised its holdings in Collegium Pharmaceutical by 1.9% in the third quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after purchasing an additional 281 shares during the period. Quadrant Capital Group LLC grew its stake in Collegium Pharmaceutical by 4.2% in the fourth quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after acquiring an additional 282 shares during the period. GAMMA Investing LLC increased its holdings in shares of Collegium Pharmaceutical by 9.6% in the fourth quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 285 shares in the last quarter. Finally, Atom Investors LP raised its position in shares of Collegium Pharmaceutical by 5.0% during the fourth quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after purchasing an additional 294 shares during the period.

Collegium Pharmaceutical Price Performance

The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. The company has a fifty day moving average price of $46.75 and a two-hundred day moving average price of $41.98. The firm has a market cap of $1.38 billion, a P/E ratio of 27.05 and a beta of 0.64.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.